Consistent with the results of omaveloxolone treatment in GBM cells, treatment with omaveloxolone downregulated the expression of CDC20 (Figure 9D), indicating its effectiveness in inhibiting the growth of GBM cells. Here, CDC20 is linked to glioblastoma.